Loading
A phase 3 trial of Lurbinectedin and Doxorubicin in uterine sarcoma, run by PharmaMar, active and no longer recruiting.
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) is a phase 3 interventional study registered as NCT06088290 by PharmaMar, with 469 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2029-08-30. Interventions recorded: Lurbinectedin and Doxorubicin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PharmaMar and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares PharmaMar and the tag pipeline.
Shares PharmaMar and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/